Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome
Authors:
Open Access
- 15 March 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1050230
Abstract
Interleukin-1 (IL-1)-blocking therapies are effective in reducing disease severity and inflammation in Schnitzler syndrome. Here, we present a patient with Schnitzler syndrome treated successfully using canakinumab for over 10 years. Complete clinical response was associated with a decrease in dermal neutrophil number and expression of the pro-inflammatory cytokines IL-1β, IL-8, and IL-17 as assessed by immunohistochemical studies.Keywords
This publication has 11 references indexed in Scilit:
- Long-term efficacy of canakinumab in the treatment of Schnitzler syndromeJournal of Allergy and Clinical Immunology, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Skin and Systemic Inflammation in Schnitzler's Syndrome Are Associated With Neutrophil Extracellular Trap FormationFrontiers in Immunology, 2019
- Schnitzler Syndrome: a ReviewCurrent Rheumatology Reports, 2017
- The role of interleukin-1 beta in the pathophysiology of Schnitzler’s syndromeArthritis Research & Therapy, 2015
- Myeloid lineage–restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndromeJournal of Allergy and Clinical Immunology, 2015
- Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromesExpert Review of Clinical Immunology, 2010
- CanakinumabmAbs, 2010
- Schnitzler’s Syndrome: Monoclonal Gammopathy Associated with Chronic UrticariaActa Haematologica, 2008
- Long-term follow-up of IgM monoclonal gammopathy of undetermined significanceBlood, 2003